Search Result

Results for "

mantle

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Adenosine Deaminase (2) Akt (1) Apoptosis (16) Btk (9) c-Myc (3) Calcium Channel (2) Caspase (5) CD19 (1) CD20 (1) CD47 (1) CDK (10) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Isomer (1) Drug-Linker Conjugates for ADC (1) EGFR (4) Epigenetic Reader Domain (2) Eukaryotic Initiation Factor (eIF) (2) Fc Receptor (FcR) (1) Ferroptosis (1) Histone Acetyltransferase (1) Histone Methyltransferase (2) HIV (1) HSP (1) IRE1 (1) MDM-2/p53 (5) Microtubule/Tubulin (3) NF-κB (3) Notch (4) Phosphatase (1) PI3K (4) PPAR (1) PROTACs (4) Proteasome (1) Reference Standards (2) ROR (1) SARS-CoV (2) Sec61 (1) Src (1) Syk (1) TNF Receptor (1) VEGFR (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (42) Cardiovascular Disease (3) Infection (3) Inflammation/Immunology (5)

By Targets:

ADC Antibody (1)

Adenosine Deaminase (2)

Akt (1)

Apoptosis (16)

Btk (9)

c-Myc (3)

Calcium Channel (2)

Caspase (5)

CD19 (1)

CD20 (1)

CD47 (1)

CDK (10)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (2)

Drug Derivative (1)

Drug Isomer (1)

Drug-Linker Conjugates for ADC (1)

EGFR (4)

Epigenetic Reader Domain (2)

Eukaryotic Initiation Factor (eIF) (2)

Fc Receptor (FcR) (1)

Ferroptosis (1)

Histone Acetyltransferase (1)

Histone Methyltransferase (2)

HIV (1)

HSP (1)

IRE1 (1)

MDM-2/p53 (5)

Microtubule/Tubulin (3)

NF-κB (3)

Notch (4)

Phosphatase (1)

PI3K (4)

PPAR (1)

PROTACs (4)

Proteasome (1)

Reference Standards (2)

ROR (1)

SARS-CoV (2)

Sec61 (1)

Src (1)

Syk (1)

TNF Receptor (1)

VEGFR (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (42)

Cardiovascular Disease (3)

Infection (3)

Inflammation/Immunology (5)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101563

GSK3326595 Maximum Cited Publications 31 Publications Verification EPZ015938	Histone Methyltransferase SARS-CoV MDM-2/p53 CDK Apoptosis	Infection Cancer
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .

HY-160141

Catadegbrutinib BGB-16673; BTK-IN-29	PROTACs Btk NF-κB	Inflammation/Immunology Cancer
BGB-16673 (BGB-16673) is an orally active, selective BTK PROTAC degrader (IC₅₀=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma .

HY-136250

BSJ-03-204	PROTACs CDK	Cancer
BSJ-03-204 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity .

HY-13599

Cladribine 5+ Cited Publications 2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA	Adenosine Deaminase Apoptosis	Cardiovascular Disease Cancer
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .

HY-19816

Avitinib 3 Publications Verification Abivertinib; AC0010	EGFR Btk Apoptosis	Cancer
Avitinib (Abivertinib) is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC₅₀ values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib shows anticancer effects .

HY-137471

RBPJ Inhibitor-1 5+ Cited Publications RIN1	Notch	Cancer
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation .

HY-103019

Enitociclib 2 Publications Verification (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib	Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Inflammation/Immunology Cancer
Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC₅₀=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .

HY-19816A

Avitinib maleate 3 Publications Verification Abivertinib maleate; AC0010 maleate	EGFR Btk Apoptosis	Cancer
Avitinib (Abivertinib) maleate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC₅₀ values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate shows anticancer effects .

HY-137438

Edralbrutinib TG-1701	Btk	Cancer
Edralbrutinib (TG-1701) is a highly selective, orally available irreversible BTK inhibitor, with an EC₅₀ of 6.70 nM and a K_d of 3 nM against human BTK. Edralbrutinib inhibits downstream signaling of the B cell receptor, induces dephosphorylation of Ikaros Ser442/445, promotes nuclear exclusion of Ikaros, attenuates Ikaros gene signatures, and exerts anti-tumor activity. Edralbrutinib can be used in research related to B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma .

HY-176763

KZR-261	Sec61	Cancer
KZR-261 is a Sec61 translocase inhibitor. KZR-261 binds directly to the Sec61 channel, thereby inhibiting the biosynthesis of certain Sec61 substrate proteins, including oncogenic factors. KZR-261 activates the endoplasmic reticulum stress response. KZR-261 exhibits broad in vitro anticancer activity. KZR-261 shows antitumor efficacy in mouse models of cancer. KZR-261 can be used for the research of multiple myeloma, colorectal cancer, small cell lung cancer, pancreatic cancer, prostate cancer, non-Hodgkin's lymphoma, and mantle cell lymphoma .

HY-176083

ASTX295	MDM-2/p53 Caspase Apoptosis	Cancer
ASTX295 is an orally active and selective MDM2 antagonist with an IC₅₀ of <1 nM. ASTX295 inhibits the MDM2-p53 interaction, activates wild-type TP53, and thereby induces the expression of relevant transcriptional targets, leading to cell death. ASTX295 drives the transition of pancreatic cancer cells from senescence to apoptosis and regulates p53 and DNA damage biomarkers. ASTX295 can be used for the research of hematologic malignancies and pancreatic cancer .

HY-P99950

Evorpacept ALX148	CD47
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .

HY-156640

Rocbrutinib LP-168	EGFR	Cancer
Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC₅₀ of 0.11 nM against wild-type BTK and an IC₅₀ of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma .

HY-16366

Briciclib ON 014185	Eukaryotic Initiation Factor (eIF) CDK c-Myc MDM-2/p53 Caspase Apoptosis	Cancer
Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-115620

AQX-016A	Phosphatase PI3K TNF Receptor	Inflammation/Immunology
AQX-016A is an orally active and potent SHIP1 agonist. AQX-016A can activate recombinant SHIP1 enzyme in vitro and stimulate SHIP1 activity. AQX-016A also can inhibit the PI3K pathway and TNFa production, can be useful for various inflammatory diseases research .

HY-15805

KIN-8194	Src Btk	Cancer
KIN-8194 is an orally active dual inhibitor of HCK and BTK, with IC₅₀ values of 0.915 and <0.495 nM, respectively. KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma (MCL). KIN-8194 overcomes ibrutinib (HY-10997) resistance with a survival benefit in TMD-8 ABC DLBCL xenografted mice .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-119966

CCT036477	Wnt β-catenin PPAR CDK	Cancer
CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .

HY-122830

DD-03-171	PROTACs Btk NF-κB	Cardiovascular Disease Cancer
DD-03-171 is a PROTAC BTK degrader. DD-03-171 inhibits mantle cell lymphoma (MCL) cell proliferation (IC₅₀ = 5.1 nM) and prolongs the survival of mice bearing a lymphoma PDX model by degrading BTK, IKFZ1, and IKFZ3. DD-03-171 also inhibits platelet function and thrombosis. (Pink: BTK ligand 9 (HY-168292); Black: linker (HY-28875); Blue: Thalidomide-NH-CH2-COOH (HY-131717)) .

HY-136250A

BSJ-03-204 triTFA	PROTACs CDK	Cancer
BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity .

HY-129336S

Abemaciclib metabolite M20-d8 LSN3106726-d₈	CDK	Cancer
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor .

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-150280

Ironomycin	Apoptosis Ferroptosis DNA/RNA Synthesis IRE1 CDK Caspase Drug Derivative	Cancer
Ironomycin is a derivative of Salinomycin (HY-15597). Ironomycin exhibits selective inhibitory activity against mantle cell lymphoma (MCL) cells. Ironomycin blocks the cell cycle and induces apoptosis and ferroptosis. Ironomycin induces double-strand DNA breaks and activates the unfolded protein response (UPR), particularly the IRE1α signaling pathway accumulation. The combination of Ironomycin with Ibrutinib (HY-10997) shows a synergistic effect. Ironomycin can be used for the study of MCL.

HY-139453A

LP-284	DNA Alkylator/Crosslinker	Cancer
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .

HY-164466

CAD204520	Calcium Channel Notch	Cancer
CAD204520, a SERCA inhibitor (IC₅₀ = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 can be used for T-ALL and MCL research .

HY-141830

SYY-B029-2	Histone Acetyltransferase	Cancer
SYY-B029-2 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 1.4 nM. SYY-B029-2 cell growth of human mantle cell lymphoma (MCL) cell line MAVER-1 and human castration resistant prostate cancer cell line LNCaP clone FGC, with IC₅₀ values of 15 nM and 13 nM, respectively .

HY-120923

GUT-70	HSP NF-κB HIV Apoptosis Caspase	Infection Cancer
GUT-70, a tricyclic coumarin, is a Hsp90 inhibitor. GUT-70 activates the caspase 2, 3, 8 and 9, and induces the apoptosis in leukemic cells. GUT-70 inhibits HIV-1 replication in chronically infected cells via suppression of the NF-κB pathway. GUT-70 can be used for the study of leukemic, mantle cell lymphoma (MCL) and HIV-1 infection .

HY-13599R

Cladribine (Standard) 2-Chloro-2′-deoxyadenosine (Standard); CldAdo (Standard); 2CdA (Standard)	Reference Standards Adenosine Deaminase Apoptosis	Cardiovascular Disease Cancer
Cladribine (Standard) is the analytical standard of Cladribine. This product is intended for research and analytical applications. Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .

HY-168427

Avitinib maleate dihydrate Abivertinib maleate dihydrate; AC0010 maleate dihydrate	EGFR Btk Apoptosis	Cancer
Avitinib (Abivertinib) maleate dihydrate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC₅₀ values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate dihydrate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate dihydrate shows anticancer effects .

HY-115944

BTK-IN-9	Btk Apoptosis	Inflammation/Immunology Cancer
BTK-IN-9 is a reversible BTK inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells. BTK-IN-9 also induces cell apoptosis in Z138 cells .

HY-176190

ROR1-IN-2	ROR	Cancer
ROR1-IN-2 (compound 9I) is a potent and selective ROR1 inhibitor. ROR1-IN-2 exhibits antiproliferative activity in multiple cancer cells. ROR1-IN-2 significantly suppresses tumor growth in vivo .

HY-151395

Tubulin polymerization-IN-34	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-34 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .

HY-151396

Tubulin polymerization-IN-35	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-35 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .

HY-151394

Tubulin polymerization-IN-33	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-33 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, exhibits high antiproliferative activity against the NCI panel .

HY-183770

LCI40	Akt PI3K Epigenetic Reader Domain c-Myc	Cancer
LCI40 is an orally active dual PI3K/BRD4 inhibitor (PI3Kα IC₅₀ = 0.071 μM, PI3Kβ IC_{50 =}0.17 μM, PI3Kγ IC₅₀ = 0.66 μM, PI3Kδ IC₅₀ = 0.072 μM, BRD4 BD1 IC₅₀ = 0.19 μM, and BRD4 BD2 IC₅₀ = 1.88 μM. LCI40 inhibits phosphorylation of pAKT (S473) and suppresses c-MYC levels in mantle cell lymphoma cells. LCI40 displays immunomodulatory capacity with minimal toxicity to normal mouse immune cells. LCI40 can be used for the research of mantle cell lymphoma .

HY-101563R

GSK3326595 (Standard) EPZ015938 (Standard)	Histone Methyltransferase Reference Standards SARS-CoV MDM-2/p53 CDK Apoptosis	Infection Cancer
GSK3326595 (Standard) is the analytical standard of GSK3326595 (HY-101563). This product is intended for research and analytical applications. GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .

HY-183922

SRX3212	PI3K Epigenetic Reader Domain	Cancer
SRX3212 is a potent PI3Kα/BRD4 inhibitor with human IC₅₀ values of 22 nM, 3.7 nM, and 32 nM for PI3Kα, BRD4_BD1, and BRD4_BD2, respectively. SRX3212 inhibits PI3K kinase activity and blocks acetyllysine binding function of BRD4_BD1 and BRD4_BD2. SRX3212 can be used for the research of mantle cell lymphoma, colon carcinoma, neuroblastoma, prostate cancer^[1].

HY-183683

DQ-9	Proteasome Apoptosis	Cancer
DQ-9 is a selective immunoproteasome β5i inhibitor (IC₅₀=0.0019 μM). DQ-9 generates additional inhibitory substances via iron-mediated intracellular activation, and induces oxidative stress, carbon-centered free radicals and macromolecular damage through its artemisinin domain. DQ-9 induces apoptosis in leukemia and multiple myeloma cells. DQ-9 exhibits selective cytotoxicity against leukemia and multiple myeloma cells by elevating the labile iron pool. DQ-9 can be used in the research of hematological malignancies (leukemia, multiple myeloma, mantle cell lymphoma, acute myeloid leukemia) .

HY-164466A

CAD204520 dihydrochloride	Calcium Channel Notch	Cancer
CAD204520 dihydrochloride, a SERCA inhibitor (IC₅₀ = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 dihydrochloride can be used for T-ALL and MCL research .

HY-P991899

IKS03 Antibody LCB73 Antibody	ADC Antibody CD19	Cancer
IKS03 Antibody (LCB73 Antibody) is an anti-human CD19 antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) .

HY-16366A

Briciclib sodium ON 014185 sodium	Eukaryotic Initiation Factor (eIF) CDK c-Myc MDM-2/p53 Caspase Apoptosis	Cancer
Briciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors .

HY-183031

BrAA-glycine-BG-PAB-Exatecan	Drug-Linker Conjugates for ADC	Cancer
BrAA-glycine-BG-PAB-Exatecan (Compound LD-11) is an Drug-Linker Conjugates for ADC, consisting of Exatecan (HY-13631) and a linker. BrAA-glycine-BG-PAB-Exatecan can be conjugated with anti-ROR1 antibodies to form an ADC .

HY-182671

SRX3305	PI3K Btk Apoptosis	Cancer
SRX3305 is an BTK/PI3K/BRD4 inhibitor with IC₅₀s of 6.5 nM, 15 nM, and 4 nM toward BTK, PI3Kɑ and PI3Kδ, respectively. SRX3305 attenuates chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) cell proliferation and promotes apoptosis in a dose-dependent fashion. SRX3305 yields potent anti-tumor effects but spares healthy bystander cells. SRX3305 inhibits the activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals. SRX3305 blocks CLL cell migration toward CXCL-12 and CXCL-13. SRX3305 maintains its anti-tumor effects in Ibrutinib (HY-10997)-resistant CLL cells. SRX3305 can be used for research in CLL, diffuse large B-cell lymphoma (DLBCL) and MCL .

HY-125585

Syk-IN-2	Syk	Others
Syk-IN-2 (Page 78; 35) is a spleen tyrosine kinase (Syk) inhibitor .

Cat. No.	Product Name	Target	Research Area	Image